Vestibular Migraine: What&#x27;s the Impact?

December 1st 2025

The Weekly Dose: Pediatric Vaccine Safety, Atopic Dermatitis, Dementia Risk, and Maternal Depression

New safety and biomarker results from MK-2214 and MK-1167 advance Merck’s dual approach to Alzheimer therapy.

August 7th 2025

FDA Approves Itvisma, First Gene Therapy for Older Children and Adults With Spinal Muscular Atrophy

Insights on atopic dermatitis treatment preferences, the safety of childhood vaccines, maternal depression’s effect on parenting, and more.

November 25th 2025

Make It Routine: Screening for Cognitive Decline in Primary Care

Novartis's Itvisma gains FDA approval as the first intrathecal gene therapy for spinal muscular atrophy, promising improved motor function and independence.

Anna Chodos, MD, MPH;Sydney Jennings

July 24th 2025

Semaglutide Fails to Slow Progression of Alzheimer Disease Compared to Placebo: Novo Nordisk Phase 3 Trial Update

Listen to our latest podcast episode to discover how early dementia detection enhances care and quality of life, with actionable strategies for primary care teams to implement now.

Bayer's Asundexian Reduces Ischemic Stroke Risk Without Raising Major Bleeding in Phase III Trial

Evoke trials testing semaglutide for Alzheimer disease missed primary endpoint, failing to demonstrate benefit on cognition despite positive effects on disease markers.

Merck Secures Fast Track for Novel AD Antibody and Reports First-in-Human Data

Topline data show the factor XIa inhibitor cut ischemic stroke risk without increasing ISTH major bleeding, pointing to a possible new option for secondary prevention.

Related Content

December 1st 2025

The Weekly Dose: Pediatric Vaccine Safety, Atopic Dermatitis, Dementia Risk, and Maternal Depression

New safety and biomarker results from MK-2214 and MK-1167 advance Merck’s dual approach to Alzheimer therapy.

August 7th 2025

FDA Approves Itvisma, First Gene Therapy for Older Children and Adults With Spinal Muscular Atrophy

Insights on atopic dermatitis treatment preferences, the safety of childhood vaccines, maternal depression’s effect on parenting, and more.

November 25th 2025

Make It Routine: Screening for Cognitive Decline in Primary Care

Novartis's Itvisma gains FDA approval as the first intrathecal gene therapy for spinal muscular atrophy, promising improved motor function and independence.

Anna Chodos, MD, MPH;Sydney Jennings

July 24th 2025

Semaglutide Fails to Slow Progression of Alzheimer Disease Compared to Placebo: Novo Nordisk Phase 3 Trial Update

Listen to our latest podcast episode to discover how early dementia detection enhances care and quality of life, with actionable strategies for primary care teams to implement now.

Bayer's Asundexian Reduces Ischemic Stroke Risk Without Raising Major Bleeding in Phase III Trial

Evoke trials testing semaglutide for Alzheimer disease missed primary endpoint, failing to demonstrate benefit on cognition despite positive effects on disease markers.